详情
Manufacturer
BAXTER ONCOLOGY GMBH(GERMANY)
Registraction Number
MAL20091970ACRZ
Content:
- Active Ingredient: Trabectedin (1 mg per vial)
Indication:
YONDELIS is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who have received a prior anthracycline-containing regimen.
Instructions:
- Dosage: The recommended dose is 1.5 mg/m² body surface area administered as an intravenous infusion over 24 hours through a central venous line every 21 days (3 weeks), until disease progression or unacceptable toxicity.
- Premedication: Administer dexamethasone 20 mg intravenously 30 minutes before each dose of YONDELIS.
- Administration:
- Administer through a central venous line.
- Monitor neutrophil count, liver function tests, and creatine phosphokinase levels before and during treatment.
- Precautions:
- Do not exceed the recommended dose.
- Avoid using strong CYP3A inhibitors and inducers.
- Inform your doctor if you have severe hepatic impairment.
- Warnings:
- Neutropenic Sepsis: Severe and fatal neutropenic sepsis may occur.
- Rhabdomyolysis: Monitor creatine phosphokinase levels.
- Hepatotoxicity: Monitor liver function tests.
- Cardiomyopathy: Patients with certain risk factors may be at increased risk.
- Embryo-Fetal Toxicity: Avoid use during pregnancy.
更多 Complete Wellness 相关资料
Malaysia
